M&A

Orexigen posts a ‘for sale’ sign in the yard as weak Contrave sales raise concerns
Orexigen posts a ‘for sale’ sign in the yard as weak Contrave sales raise concerns
Endpoints
Orexigen
Contrave
M&A
Flag link:
Things Get Ugly Between NuVasive and Alphatec
Things Get Ugly Between NuVasive and Alphatec
Medical Device and Diagnostic Industry
NuVasive
Alphatec
devices
M&A
Flag link:
Reckitt Benckiser is the most likely buyer of Pfizer’s Consumer Healthcare business
Reckitt Benckiser is the most likely buyer of Pfizer’s Consumer Healthcare business
GoinPharma
Reckitt Benckiser
Pfizer
M&A
consumer health
Flag link:
3 Signs Myriad Genetics' High-Growth Days Are Over
3 Signs Myriad Genetics' High-Growth Days Are Over
Motley Fool
Myriad Genetics
M&A
competition
Flag link:
3 Reasons Why Pfizer Investors Will Win With a Consumer Business Sale or Spinoff
3 Reasons Why Pfizer Investors Will Win With a Consumer Business Sale or Spinoff
Motley Fool
Pfizer
consumer health
M&A
Flag link:
Express Scripts drops $3.6B for healthcare management company
Express Scripts drops $3.6B for healthcare management company
Biopharma Dive
Express Scripts
M&A
healthcare management
eviCore
Flag link:
Pfizer to explore potential sale, spinoff of consumer healthcare business
Pfizer to explore potential sale, spinoff of consumer healthcare business
Marketwatch
Pfizer
consumer health
M&A
Flag link:
Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit
Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit
Yahoo/Zacks.com
Emergent BioSolutions
Sanofi
M&A
smallpox
vaccines
ACAM2000
Flag link:
Flexion nabs FDA OK for its potential blockbuster osteoarthritis drug, triggering new buyout buzz
Flexion nabs FDA OK for its potential blockbuster osteoarthritis drug, triggering new buyout buzz
Endpoints
Flexion
FDA
osteoarthritis
M&A
Zilretta
Flag link:
Sanofi hires banks to look for buyers of Zentiva
Sanofi hires banks to look for buyers of Zentiva
GoinPharma
Sanofi
Zentiva
M&A
Flag link:
Abbott completes Alere tender offer
Abbott completes Alere tender offer
Mass Device
Abbott Labs
Alere
M&A
diagnostics
devices
Flag link:
From mega-merger to big bang?
From mega-merger to big bang?
Elsevier
M&A
R&D
Flag link:
Endo, feeling the pricing squeeze, could be the next generics player on the hunt for M&A: Analyst
Endo, feeling the pricing squeeze, could be the next generics player on the hunt for M&A: Analyst
Fierce Pharma
Endo International
M&A
Flag link:
Does Pfizer really want Bristol-Myers? Likely, says one analyst. What's it waiting for?
Does Pfizer really want Bristol-Myers? Likely, says one analyst. What's it waiting for?
Fierce Pharma
Pfizer
Bristol-Myers Squibb
M&A
Flag link:
Arcturus to go public through merger with Alcobra
Arcturus to go public through merger with Alcobra
BioPharma Dive
Arcturus
Alcobra
M&A
Flag link:
UPDATE: Abbott plans to close $5B Alere buyout next week
UPDATE: Abbott plans to close $5B Alere buyout next week
Mass Device
Abbott
Alere
M&A
devices
Flag link:
Why would Novartis buy a $2.6B radiotherapy maker? Its neuroendocrine franchise, analyst says
Why would Novartis buy a $2.6B radiotherapy maker? Its neuroendocrine franchise, analyst says
Fierce Pharma
Novartis
radiotherapy
M&A
Advanced Accelerator Application
neuroendocrine
Flag link:
Buyout buzz: Novartis has been kicking the tires at AAA as FDA reviews Lutathera — report
Buyout buzz: Novartis has been kicking the tires at AAA as FDA reviews Lutathera — report
Endpoints
Novartis
FDA
Lutathera
M&A
Advanced Accelerator Application
Flag link:
Biotech: The Big Payoff
Biotech: The Big Payoff
Seeking Alpha
biotech
Gilead Sciences
M&A
Flag link:
Why Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion?
Why Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion?
Motley Fool
Gilead Sciences
taxes
Kite Pharma
M&A
Flag link: